Michal Kovac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9348495/publications.pdf

Version: 2024-02-01

28 papers

1,738 citations

16 h-index 27 g-index

29 all docs 29 docs citations

29 times ranked

4429 citing authors

#	Article	IF	Citations
1	Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology, 2014, 59, 911-923.	7.3	382
2	Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nature Communications, 2015, 6, 8940.	12.8	242
3	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	12.8	100
4	Combined analysis of specific <i>KRAS</i> mutation, <i>BRAF</i> and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer, 2010, 127, 2569-2575.	5.1	99
5	The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2018, 2, 1661-1672.	7.8	99
6	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. Gastroenterology, 2015, 148, 367-378.	1.3	93
7	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. British Journal of Cancer, 2013, 109, 827-835.	6.4	91
8	Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nature Communications, 2016, 7, 11111.	12.8	83
9	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell, 2017, 31, 79-93.	16.8	83
10	Genomeâ€wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma. International Journal of Cancer, 2017, 141, 816-828.	5.1	83
11	Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget, 2017, 8, 48794-48806.	1.8	70
12	Evidence for breast cancer as an integral part of lynch syndrome. Genes Chromosomes and Cancer, 2012, 51, 83-91.	2.8	57
13	Activating mutations in the MAPâ€kinase pathway define nonâ€ossifying fibroma of bone. Journal of Pathology, 2019, 248, 116-122.	4.5	49
14	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology, 2015, 28, 1336-1342.	5.5	47
15	Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. British Journal of Cancer, 2015, 113, 686-692.	6.4	30
16	Multiplex SNaPshot Genotyping for Detecting Loss of Heterozygosity in the Mismatch-Repair Genes MLH1 and MSH2 in Microsatellite-Unstable Tumors. Clinical Chemistry, 2008, 54, 1844-1854.	3.2	18
17	Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patientâ€derived osteosarcoma cells and synergizes with cisplatin and talazoparib. International Journal of Cancer, 2020, 147, 1059-1070.	5.1	17
18	<i>NTRK</i> fusions in osteosarcoma are rare and nonâ€functional events. Journal of Pathology: Clinical Research, 2020, 6, 107-112.	3.0	17

#	Article	IF	CITATIONS
19	3′-UTR Poly(T/U) Tract Deletions and Altered Expression of <i>EWSR1</i> Are a Hallmark of Mismatch Repair–Deficient Cancers. Cancer Research, 2014, 74, 224-234.	0.9	16
20	Loss of <scp><i>NF2</i></scp> defines a genetic subgroup of <scp>nonâ€<i>FOS</i></scp> â€rearranged osteoblastoma. Journal of Pathology: Clinical Research, 2020, 6, 231-237.	3.0	11
21	SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules. European Journal of Cancer, 2014, 50, 731-738.	2.8	9
22	The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies. Journal of Pathology, 2021, 254, 556-566.	4.5	9
23	Familial colorectal cancer: eleven years of data from a registry program in Switzerland. Familial Cancer, 2011, 10, 605-616.	1.9	8
24	Germline RET variants underlie a subset of paediatric osteosarcoma. Journal of Medical Genetics, 2021, 58, 20-24.	3.2	7
25	Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?. Journal of Pathology: Clinical Research, 2021, 7, 165-172.	3.0	7
26	DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma. PLoS Computational Biology, 2021, 17, e1009562.	3.2	6
27	Convergent Evolution of Copy Number Alterations in Multi-Centric Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 4611.	3.3	2
28	Osteosarcoma of the Mandible in a Patient with Florid Cemento-Osseous Dysplasia and Li–Fraumeni Syndrome: A Rare Coincidence. Head and Neck Pathology, 2021, 15, 704-708.	2.6	2